Selected Publications
Molecular Neurosurgery Laboratory
Samuel David Rabkin, PhD

Dr Rabkin | Bios  |  Links | Molecular Neurosurgery Laboratory

National Libraries of Medicine National Institutes of Health PubMed Search

Rabkin Publications Rabkin Pubs 2007 Rabkin Pubs 2006 Rabkin Pubs 2005 Rabkin Pubs 2004 Rabkin Pubs 2003 Rabkin Pubs 2002 Rabkin Pubs 2001 Rabkin Pubs 2000 Rabkin Pubs 1999

1: Jorgensen TJ, Katz S, Wittmack EK, Varghese S, Todo T, Rabkin SD, Martuza RL.

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001 Sep-Oct;3(5):451-6.

2: Varghese S, Newsome JT, Rabkin SD, McGeagh K, Mahoney D, Nielsen P, Todo T, Martuza RL.

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther. 2001 May 20;12(8):999-1010.

3: Todo T, Martuza RL, Rabkin SD, Johnson PA. , Free in PMC

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401.

4: Toda M, Martuza RL, Rabkin SD.

Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001 Feb;8(4):332-9.

5: Mashour GA, Moulding HD, Chahlavi A, Khan GA, Rabkin SD, Martuza RL, Driever PH, Kurtz A.

Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.
Exp Neurol. 2001 May;169(1):64-71.

6: Wu A, Mazumder A, Martuza RL, Liu X, Thein M, Meehan KR, Rabkin SD.

Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 2001 Apr 1;61(7):3009-15.

7: Todo T, Martuza RL, Dallman MJ, Rabkin SD.

In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001 Jan 1;61(1):153-61.

8: Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL.

Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther. 2000 Dec;2(6):588-95.

9: Toda M, Martuza RL, Rabkin SD.

Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000 Oct;2(4):324-9.

10: Jasmin L, Janni G, Ohara PT, Rabkin SD.

CNS induced neurogenic cystitis is associated with bladder mast cell degranulation in the rat.
J Urol. 2000 Sep;164(3 Pt 1):852-5.

11: Chahlavi A, Todo T, Martuza RL, Rabkin SD.

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999 Jun;1(2):162-9.

12: Moulding HD, Martuza RL, Rabkin SD.

Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression.
J Neurosci. 2000 Aug 1;20(15):5696-702.

13: Todo T, Rabkin SD, Martuza RL.

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000 Jun;7(6):939-46.

14: Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000 May;7(10):867-74.

15: Sundaresan P, Hunter WD, Martuza RL, Rabkin SD.

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.
J Virol. 2000 Apr;74(8):3832-41.

16: Todo T, Rabkin SD, Chahlavi A, Martuza RL.

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999 Nov 20;10(17):2869-78.

17: Todo T, Rabkin SD, Sundaresan P, Wu A, Meehan KR, Herscowitz HB, Martuza RL.

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999 Nov 20;10(17):2741-55.

18: Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL.

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999 Sep 1;10(13):2237-43.

19: Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD.

Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
Gene Ther. 1999 Apr;6(4):564-72.

20: Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD.

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999 Aug;73(8):6319-26.

Neurosurgery Clinical Units MGH Neurosurgical Service Spine Tumor Center at MGH Brain Tumor Center at MGH Research at MGH Neurosurgery Neuroscience Care Units at MGH Residents at Neurosurgery